3-Minute Guide: What Happens When You Stop Taking a GLP-1 Drug
Adrian Carter·Former metabolic disease researcher turned health writer. Breaks down how hormones like GLP-1 shape your weight, appetite, and energy — no jargon required.··5 min read
3-Minute Guide: What Happens When You Stop Taking a GLP-1 Drug
Most people who stop a GLP-1 receptor agonist (GLP-1 RA) regain roughly two-thirds of the weight they lost within a year. That finding comes not from a single study but from multiple large-scale clinical trials and meta-analyses published in the world's top journals — and understanding why it happens can help you make a more informed decision with your doctor.
This guide covers the biology behind the rebound, what the timeline looks like week by week, how different drugs compare, and what limited strategies exist for slowing that regain down.
Why Your Appetite Comes Back So Fast
GLP-1 receptor agonists suppress hunger through several simultaneous pathways. They activate GLP-1 receptors in the hypothalamus and brainstem to dial down hunger signals, slow gastric emptying so you feel full longer, and stimulate vagal nerve fibers that carry satiety messages from the gut to the brain. One less obvious mechanism involves leptin, a hormone that signals the brain how much fat the body is storing.
When you lose weight, your body normally compensates by raising levels of the soluble leptin receptor, which acts like a sponge and reduces the amount of free leptin available to signal satiety. GLP-1 drugs appear to suppress that compensatory rise, keeping free leptin higher than it would otherwise be during weight loss[12]. In other words, the drug was partly helping you maintain your appetite suppression by working around your body's own counter-regulation.
Stop the drug, and all of those mechanisms switch off at once. Hunger signaling resumes within days to weeks as the drug clears your system. Soluble leptin receptor levels climb, free leptin drops, and the brain's defended weight "set point" reasserts itself by driving energy intake upward. Gastric emptying returns to its baseline speed, reducing how long meals keep you feeling satisfied. The biology is not a personal failing — it is the same adaptive response the body uses any time significant weight is lost, now unmasked.
The Week-by-Week Rebound Timeline
A 2025 systematic review and meta-analysis in BMC Medicine tracked weight changes at multiple time points after GLP-1 drug discontinuation across pooled trial data. The picture that emerges is of a slow start that accelerates quickly.
Frequently Asked Questions
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
AC
Adrian Carter
Former metabolic disease researcher turned health writer. Breaks down how hormones like GLP-1 shape your weight, appetite, and energy — no jargon required.
Former metabolic disease researcher turned health writer. Breaks down how hormones like GLP-1 shape your weight, appetite, and energy — no jargon required.
In the first four weeks, the measured regain is minimal and not statistically significant. By week 8, participants had gained an average of 1.50 kg more than controls (p < 0.0001). By week 12, that figure reached 1.76 kg, and by week 20 it had climbed to 2.50 kg. These numbers sound modest in isolation, but the large-scale withdrawal trials tell the fuller story at the 12-month mark.
The STEP 1 trial extension followed participants for 52 weeks after stopping semaglutide 2.4 mg. By that point, participants had regained approximately 11.6 percentage points of body weight, representing about two-thirds of what they had lost during treatment. Net weight change from the original baseline was only 5.6% at the end of the extension period, compared with 17.3% lost during active treatment[1]. In practical terms: if you lost 20 kg on the drug, you might expect to weigh about 13 kg above that low point a year after stopping, leaving a net loss of roughly 7 kg from where you started.
How Much Weight You Regain Depends on Which Drug You Were Taking
Not all GLP-1 drugs produce the same degree of regain after stopping, and the reason is straightforward: the agents that help you lose the most weight also leave you with the most to re-accumulate.
A 2025 meta-analysis in Obesity Reviews pooled data from 8 randomized controlled trials (RCTs) involving 2,372 participants[6]. It found that people stopping liraglutide regained an average of 2.20 kg (95% CI 1.69 to 2.70), while those stopping semaglutide or tirzepatide regained nearly five times as much — 9.69 kg (95% CI 5.78 to 13.60). A separate 2025 meta-analysis in EClinicalMedicine reported semaglutide users regaining 8.21 kg versus 4.29 kg for liraglutide users, and showed that studies with follow-up beyond 26 weeks documented 7.31 kg of regain compared with only 2.51 kg in shorter-term studies[7].
Tirzepatide data from the SURMOUNT-4 trial paints one of the starkest pictures. Participants who completed 36 weeks of tirzepatide treatment and were then switched to placebo gained 14.0% of body weight between weeks 36 and 88. Only 16.6% of the withdrawal group maintained at least 80% of their weight loss, compared with 89.5% of those who stayed on the drug[3]. The weight class is important here: tirzepatide acts on both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, producing larger initial losses, which means larger absolute rebounds when stopped.
What Happens to Your Metabolic Health
Weight regain is not just a number on the scale. The cardiometabolic improvements that GLP-1 drugs deliver during treatment largely reverse when the weight comes back, and the degree of reversal tracks closely with how much weight is regained.
A post hoc analysis of SURMOUNT-4 published in JAMA Internal Medicine in 2026 divided the withdrawal group by how much of their lost weight they had regained[4]. Those who regained 75% or more of lost weight saw waist circumference increase by up to 14.7 cm, systolic blood pressure rise by 6.8 to 10.4 mm Hg, HbA1c climb by 0.14% to 0.35%, fasting insulin surge by up to 46.2%, and non-HDL cholesterol increase by up to 10.8%. A 2025 meta-analysis corroborated this across a broader population, reporting average HbA1c increases of 0.25% in people with obesity and 0.65% in those with type 2 diabetes after stopping GLP-1 drugs[7].
The STEP 1 extension reported that inflammatory markers (C-reactive protein, or CRP) also returned toward baseline during the post-treatment year, alongside the deterioration in blood pressure and glycemic control[1]. The cardiovascular context is worth noting: the SELECT trial established that continuous semaglutide 2.4 mg use reduced major adverse cardiovascular events by 20% (HR 0.80; 95% CI 0.72 to 0.90) in adults with obesity and established cardiovascular disease[5]. That protective effect was contingent on continued treatment, and the SURMOUNT-4 post hoc data suggest that the cardiometabolic risk restored by weight regain after stopping would progressively erode it.
Can Anything Slow the Regain?
The honest answer is: not much, in most people. The STEP 1 extension included lifestyle intervention support throughout the post-treatment year — structured counseling on diet and activity — and two-thirds of lost weight was still regained[1]. The STEP 4 trial, which switched participants from semaglutide to placebo at 20 weeks, found a 14.8 percentage point difference in weight outcomes between continued and discontinued groups by week 68[2], reinforcing that the drug itself was doing the heavy lifting, not lifestyle measures alone.
One hypothesis-generating exception comes from a 2024 observational study of 25 women with polycystic ovary syndrome (PCOS) and obesity who continued metformin after stopping semaglutide[11]. Over two years, this group regained only about one-third of their semaglutide-induced weight loss, and 84% remained below their pre-treatment weight. Roughly two-thirds of the initial 9 kg weight loss was preserved, compared with two-thirds typically lost in trials without adjunct therapy. This is a small, single-center study in a specific population, so it cannot be generalized — but it points toward adjunct pharmacotherapy as a potential partial strategy worth discussing with a prescribing physician.
What the broader data suggest is that GLP-1 drugs function more like glasses than like a one-time corrective procedure: the benefit largely depends on continued use. For many people, this changes how to think about these medications — not as a course of treatment with a defined end date, but as an ongoing management tool, similar to blood pressure or cholesterol medications.
Frequently Asked Questions
Q. How quickly do you start regaining weight after stopping a GLP-1 drug?
Regain begins within the first two months of stopping. A systematic review found that measurable regain appears by week 8, with statistically significant increases continuing through at least week 20[9]. The pace accelerates over the following months, and by the one-year mark most trials show roughly two-thirds of lost weight has returned[1].
Q. Is stopping a GLP-1 drug permanent, or can you restart?
Restarting is possible and some people cycle on and off these medications under physician supervision. The clinical data on restart outcomes are limited, but the underlying biology suggests that restarting would re-engage the same appetite-suppressing pathways and produce weight loss again. Any decision to stop or restart should be made with a qualified healthcare provider.
Q. Does stopping a GLP-1 drug affect blood sugar and blood pressure, not just weight?
Yes. Stopping GLP-1 drugs reverses most of the cardiometabolic improvements achieved during treatment. Studies show that blood pressure, HbA1c, fasting insulin, and cholesterol markers all trend back toward pre-treatment levels, with the degree of deterioration proportional to how much weight is regained[4][7]. People with type 2 diabetes, in particular, may see their glycemic control worsen after stopping[7].
Q. Does how long you took the drug affect how much weight you regain?
Current evidence suggests treatment duration does not protect against regain. A narrative review of randomized studies on liraglutide, semaglutide, and tirzepatide concluded that rapid regain occurs regardless of how long the patient was on therapy[10]. The SURMOUNT-4 post hoc analysis reached a similar conclusion: stopping after 36 weeks still produced substantial weight regain.
Q. Is the weight regain the same for all GLP-1 drugs?
No. Drugs that produce greater weight loss tend to produce greater absolute regain. In pooled analyses, stopping liraglutide was associated with roughly 2 to 4 kg of regain, while stopping semaglutide or tirzepatide was associated with 8 to 14 kg or more[6][7][3]. This pattern reflects the proportionality between initial weight loss and the body's homeostatic drive to restore the prior weight.
References
[1] Wilding JPH, Batterham RL, Davies M, Van Gaal LF, et al., "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension," Diabetes, Obesity and Metabolism, 2022. DOI: 10.1111/dom.14725
[2] Rubino D, Abrahamsson N, Davies M, et al., "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial," JAMA, 2021. DOI: 10.1001/jama.2021.3224
[3] Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, et al., "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial," JAMA, 2024. DOI: 10.1001/jama.2023.24945
[4] Horn DB, Linetzky B, Davies MJ, Laffin LJ, Wang H, Murphy MA, et al., "Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial," JAMA Internal Medicine, 2026. DOI: 10.1001/jamainternmed.2025.6112
[5] Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT Trial), New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2307563
[6] Berg S, Stickle H, Rose SJ, Nemec EC, "Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis," Obesity Reviews, 2025. DOI: 10.1111/obr.13929
[7] Tzang CC, Wu PH, Luo CA, et al., "Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis," EClinicalMedicine, 2025. DOI: 10.1016/j.eclinm.2025.103680
[9] Wu H, Yang W, Guo T, Cai X, Ji L, "Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications," BMC Medicine, 2025. DOI: 10.1186/s12916-025-04200-0
[10] Quarenghi M, Capelli S, Galligani G, et al., "Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies," Journal of Clinical Medicine, 2025. DOI: 10.3390/jcm14113791
[11] Jensterle M, Ferjan S, Janez A, "The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study," Frontiers in Endocrinology, 2024. DOI: 10.3389/fendo.2024.1366940
[12] Iepsen EW, Lundgren J, Dirksen C, et al., "Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss," International Journal of Obesity, 2015. DOI: 10.1038/ijo.2014.177
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
